Tandem Diabetes Care, Inc. (TNDM)
| Market Cap | 1.17B -5.7% |
| Revenue (ttm) | 1.08B +6.8% |
| Net Income | -49.24M |
| EPS | -0.72 |
| Shares Out | 69.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,295,268 |
| Open | 17.08 |
| Previous Close | 17.05 |
| Day's Range | 16.45 - 17.75 |
| 52-Week Range | 12.26 - 29.65 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | 27.10 (+61.31%) |
| Earnings Date | Nov 5, 2026 |
About TNDM
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. Itās flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the userās body. In addition, it offers Tandem Device Updater used to update the pump software from a pe... [Read more]
Financial Performance
In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price target is $27.1, which is an increase of 61.31% from the latest price.
News
Stifel upgrades Tandem to Buy, notes share gains and improving margins
Stifel upgraded Tandem Diabetes (TNDM) to Buy from Hold with a price target of $26, up from $22. For future tubeless entrants, Tandemās tubeless Mobi scored well, with 2028 shareā¦
Tandem Diabetes upgraded to Buy from Hold at Stifel
Stifel analyst Jonathan Block upgraded Tandem Diabetes (TNDM) to Buy from Hold with a price target of $26, up from $22.
Tandem Diabetes receives FDA clearance for Tandem Mobi
Tandem Diabetes (TNDM) Care announced U.S. Food and Drug Administration clearance of Tandem Mobi for use as the worldās first and only tubeless automated insulin delivery system with up toā¦
Tandem Mobi Now FDA Cleared as World's First and Only Tubeless AID System with up to Seven Days of Wear
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (F...
Tandem Diabetes announces receipt of Health Canada approval for t:slim X2
Tandem Diabetes (TNDM) Care announced receipt of Health Canada approval of a license amendment for the t:slim X2 insulin pump with Control-IQ+ automated insulin delivery, AID, technology. This approva...
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval o...
Tandem Diabetes price target lowered to $25 from $27 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firmās price target on Tandem Diabetes (TNDM) to $25 from $27 and keeps an Overweight rating on the shares. The firm highlights theā¦
Tandem Diabetes price target raised to $20 from $18 at Mizuho
Mizuho raised the firmās price target on Tandem Diabetes (TNDM) to $20 from $18 and keeps a Neutral rating on the shares.
Tandem Diabetes price target raised to $20 from $18 at Barclays
Barclays raised the firmās price target on Tandem Diabetes (TNDM) to $20 from $18 and keeps an Equal Weight rating on the shares.
Tandem Diabetes Care Earnings Call Transcript: Q3 2026
Q3 revenue rose 14% and gross margin expanded as pharmacy and international direct operations advanced. Pharmacy adoption is gradual, creating revenue headwinds into 2027; FY2026 guidance was maintained, alongside a planned CEO transition.
Tandem Diabetes Care Earnings release: Q3 2026
Tandem Diabetes Care released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Tandem Diabetes Care Quarterly report: Q3 2026
Tandem Diabetes Care has published its Q3 2026 quarterly earnings report on November 5, 2026.
Tandem Diabetes Care Slides: Q3 2026
Tandem Diabetes Care has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Tandem Diabetes names Jeannette Bankes president, CEO
Tandem Diabetes (TNDM) Care announced the appointment of Jeannette Bankes as president and chief executive officer (āCEOā), and a member of its Board of Directors, effective November 16, 2026. Ms.
Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Jeannette Bankes named President and CEO of Tandem Diabetes Care in planned transition as John Sheridan Retires After Over a Decade of Service.
Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter end...
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the ...
Tandem Diabetes price target lowered to $18 from $20 at Mizuho
Mizuho analyst Anthony Petrone lowered the firmās price target on Tandem Diabetes (TNDM) to $18 from $20 and keeps a Neutral rating on the shares. The firm adjusted targets inā¦
Tandem Diabetes initiated with an Equal Weight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Tandem Diabetes (TNDM) with an Equal Weight rating and $18 price target The firm rolled out coverage of the medical suppliers and devicesā¦
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial m...
Citi cuts Tandem target, opens āupside 90-day catalyst watchā
Citi analyst Joanne Wuensch lowered the firmās price target on Tandem Diabetes (TNDM) to $20 from $24 and keeps a Neutral rating on the shares. Citi also opened an āupsideā¦
Tandem Diabetes says Tandem Mobi now available in 12 international markets
Tandem Diabetes (TNDM) Care announced that Tandem Mobi, the worldās smallest, durable automated insulin delivery system for people living with diabetes, is now available in 12 countries outside the Un...
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Tandem Diabetes initiated with an Outperform at William Blair
William Blair initiated coverage of Tandem Diabetes (TNDM) with an Outperform rating. The firm believes the company is positioned to be the next player to enter the tubeless pump market.
Tandem Diabetes price target raised to $24 from $21 at Citi
Citi analyst Joanne Wuensch raised the firmās price target on Tandem Diabetes (TNDM) to $24 from $21 and keeps a Neutral rating on the shares. The firm is more optimisticā¦